ABSTRACT
Figure 10.1 Commonly used labelling strategies for LPs, depending on the location of the RN. The interested reader is referred to a number of excellent reviews on LP radiolabelling [5, 6]. In this chapter, we intend to provide an updated overview of the different strategies that have been used to prepare radiolabelled LPs with positron and g emitters. Selected examples of radiolabelled LPs and their use in vivo will be discussed. The use of therapeutic isotopes is covered in Chapter 15 and will not be discussed here; radiolabelling using low-energy b-emitters, such as 3H and 14C, is beyond the scope of this book.In alphabetical order, the following abbreviations are used in this chapter: CHOL: cholesterol; DOTA: 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid; DMPC: 1,2-dimyristoyl-sn-glycero-3-phosphocholine; DMPG: 1,2-dimyristoyl-sn-glycero-3phosphoglycerol; DPPC: 1,2-dipalmitoyl-sn-glycero-3-phosphocholine; DPPG: 1,2-dipalmitoyl-sn-glycero-3-phosphoglycerol; DSPC: 1,2-distearoyl-sn-glycero-3-phosphocholine; DSPE: 1,2-dis-tearoyl-sn-glycero-3-phosphoethanolamine; DTPA: diethylenetri-aminepentaacetic acid; NTA: nitrilotriacetic acid; PBS: phosphate buffered saline; PC: phosphatidylcholine; PE: phosphatidylethanolamine; PEG: polyethylene glycol; POPC: 1-palmitoyl,2-oleoyl-sn-glycero-3-phosphocholine; SA: stearylamine.
